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plaatyaccording to different times to enrollment (p= 0.31 for death, p =0.14
for death, reMl or stroke). Nevetiheless, these data suggest that the advan-
tage of direof angioplasty over thrombolyfic therapy may tvaless important in
the early hom following symptom onset.
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El7812 Prehospltal Thrombolysis is Associated With
Superior Myocardial Reperfusion: a Grampian
Region Early Anlstraplase Trial (GREAT) Sub Study
R.J. Trent, J.N. Adams, J.M. Rawles. Cait7/acDep8ftment, Abe-n Royal
Infirmary & Medicines Researoh Unit, Aberdeen Univeraify Scotland, UK
The benefits of thrombolysis are related to the speed of reperfusion of
the infarct-related artery. In this GREAT substudy, we have examined the
Incidence of earfy reperfusion in patients receiving pre hospital and standard
thrombolysls. In a randomised, double-blind controlled trial, 311 Patients
with suspected acute myocardlal infarction were given anistreplase 30 Units
iv., either at home (n = 163), or upon arrival in hospital (n = 148). The
median times to treatment after symptom onset were 101 and 240 minutes,
respectively. Paired electrocardiograms (ECG) were recorded at home and
on admission to hospital were available for study in 143 and 137 of the
pre hospital and hospital treatment groups, respectively. Reduction in ST
elevation between home and hospital ECGSof >25% and >50% of maximal
in the lead demonstrating greatest elevation at presentation (ST el Max) and
summatad ST elevation (X ST el) s20% were used to define reperfusion.
Patients with significant ST elevation in either ECG comprised the sub
study groups, and numbered 6EW43 (44%) and 66/137 (50%) of the pre
hospital and hospital treatment groups, respectively.A reduction of >20% in
2 STel was present in 31 (49%)of the pre hospital thrombolysis group, and
20 (29%) of the hospital treatment group (difference 20%, 95% Cl 3 to 36%,
p = 0.003). A reduction of >25°A ST el max was associated with a lower
incidence of death (6 [IO%] vs 16[23%], difference 13Y0,95% Cl Oto 25%, p
= 0.047) and q wave infarction (37 [62%] vs 84 [90%], difference 29%, 95%
cl14 to 43%, p = o.0ooo6).
The use of pre hospitai thrombcdysis in this study was associated with
increased early reperfusion. This finding, whether spontaneous or following
thrombolysis, was associated with a better outcome.
11:00
~1 Red.~,~n~fre..rre.ti..hem~,thabai.imib.b
during continuous ECG-iachemia monitoring in
patienta with unatable angina refractory to standard
treatment (CAPTURE)
P.Klootwijk, S. Meij, R. Melkerf, M.L. Simoons. Tftorsxcerder Univ Hospital
Roftenfam-Dijkzigt, The Netherlands
In the CAPTURE trial, 1288 patients with refractory unstable angina were
treated with aboiximabor placebo on top of standard treatment from 24hours
preceding coronary intewention until 1 hour after. In order to investigate the
incidenceof recurrent iachemia and ischemicburden, asubsetof332 patients
underwent mntinuous vector-derived 12-lead ECG-ischemia monitoring from
start of treatment until 6 hours afferthe coronary intervention.
Total isohemic burden wascalculatad asthetotal duration of ST-episcdes
per patient, the area under the cuwe of the ST-vacfor-magnitude (ST-VM)
during episcdes and the summated areas under the curves of 12 leads (12
lead) during episodes.
ST-episdes were detected in 31 (18Y0)of the 169 abciximab and in 37
(23%) of the 163 placebo patients (n.s). Only 5 abciximab patients (3%)
vs. 15 placebo patients (90A)had ? 3 ST-episcdes (p c 0.02). In patients
with ischemia, aboiximab raducad total ischemic burden (median, 25, 75
percentiles):
Abciximsb Placebo p-value
Duration(mIn) s (4,30) se (5,89) <0.02
ST-VM(pV.min) 796(483,2613) 4619(748,17143) <0.01
t2 lead(#V.min) 5376(2696,14131) 29392(4821,114864) <0,01
21 patienta (6%) had a myocardial infarction (18) or died (3) within 5
daye of treatment. The presence of cheat pain during the monitoring period
preceding coronary intervention was associated with an increaaed relative
rick (95°ACl) of 2.6 (1.2, 6.0) of these events. For asymptomatic and symp-
tomatic ST-episodes the relative risks of these events were 3.2 (1.4, 7.4) and
4.1 (1.4, 12.2), respectively.
We conclude that treatment with abciximab ia associated with a raduction
of frequent ischemia and a reduction of total ischemic burden in patients with
refractoryunstable angina. Recurrent ischemia predicts myocardial infarction
or death within 5 days.
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Impact of Early Reperfueion Therapy on Patency
and Survivat in Diabetic va Nondiabatic Patienta
With Acute Myocardiat Infarction
D. Karila-Cohen, P.G.Steg, J.-M. Juliard, H. Benamer, D. Himbert,
M.-C. Aumont. Seivice de Cardiobgie, Hopita/Bichat, Paris, France
Patients with diabetes meilitus (DM+) treatad by thrombcrlysis (Thr) during
the acute phase of myocardial infarction (Ml) have a worse outcome than Pta
without DM (DM–). The aim of this study was to aseess outcome in Pfa with
DM when treated with an “agressive” reperfusion strategy (i.e. thrombolyais
followed by rescue PTCA if neceess~, or primary PTCA). We retrospacfively
studied 661 Pfs admitted <6 houm after acute Ml “(DM+= 66, DM- = 575).
Reparfusion therapy was: thrombolysis in 47Ya (including 26% of rescue
PTCA) and primaty PTCA in 41% of Pts.
DM+(n= 88) DM–(n=575) p
Age 61 + 1.2 58+ 0.6 0.0s
Hypartansion 47”, 34% O.ot
Multivesseldisease 610/a 40% 0.01
Reperfusiontherapy 89”/& 88% NS
TIMI3 afterreperfusiontherapy 79°k 91% 0.01
TIMI3 afterlhrombolysis 47% 62% 0.1
TIMI 3 after prhnsry or rescue PTCA 83”% 94”h 0,01
In-hospital death 10.6°YA 7.9?. NS
Shock 8.1% 3.7% 0,05
Pulmonary edema 18% 9% 0.03
Laffventricular ejection fraclion (%) 47.2 + 2.3 51.6 * 0.7 0,03
Diabetic Pts have worse baseline characteristics. Despite similar use of
reperfusion therapy, they achieve lower acute patency rates. This is associ-
ated with a worse in-hospital outcome, Including a trend towards in increased
mortality.
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the Ut!inetion of Acute Raparfusion Therapy for
Acute Myocardial InfarctIon: Resuits from the NRMI
2
J.G. Canto, W.J. Rogers, W.J. French, J.M. Gore, N.C. Chandra, R. Perdok
for the NRMI 2 Investigator. University of A/absme Medical Centefi
Birmingham, AL, USA
In order to ascertain the influence of regional variability and payer status on
the utilization of acute reperfusion therapies for myocardial infarction in the
US, data among 275,046 patients enrolled from June 1994 to April 1996 in
the National Registry of Myocardial Infarction 2 were compared between the
9 US Ceneus regions and payer groups.
% Utilizationof Acute ReperfusionTherapies*
All Payers* Privete* HMO* Medicare* Medicaid* Salt-pay;
All regionst
N Englandt
Mid-A!lantlct
S Atlantict
E N Central+
E S Centralt
W N Centrslt
W S Centrslt
Mountaint
Pacitict
37 51 45 27 38 53
34 47 43 24 27 49
30 46 43 20 29 45
37 51 46 27 32 51”
36 51 46 26 38 53
41 54 55 30 43 57
39 53 50 30 39 57
43 58 51 31 34 57
45 55 44 37 46 61
38 51 42 28 39 5a
30-45 4S-58 42-55 20-37 27-46 45-81
* IV/lCthrombolysis, primary PTCAorimmediata CABG, *p c 0.001 bstween ragions; tp
<0.001 within each region.
Cone/usion:Considerable regional variability was present in the utilization
of reperfusion therapy for acute myocsrdial infarction throughout the 9 US
census regions and was highest in the Mountain region (45%) and lowest
in Mid-Atlantic (30%). Significant regional variation was also present within
each payer group. Medicare and medicaid recipients have a relative dispro-
portionate number of patients who do not receive acute reperfusion therapy
compared to other groups.
